Switglim MV 2/0.3 Tablet ER
strip of 10.0 tablet.Prescription required
About this product:
| Salt Composition: | Glimepiride (2mg) + Metformin (500mg) + Voglibose (0.3mg) |
| Manufacturer: | Akumentis Healthcare Ltd |
| Storage: | Below 25 degree celcius |
Out of Stock
Have doubts about this medicine?
Have doubts about this medicine?
Switglim MV 2/0.3 Tablet ER is a combination of medicines used to treat type 2 diabetes mellitus in adults, helping to control blood sugar levels. Switglim MV 2/0.3 Tablet ER belongs to a category of medicines known as anti-diabetic drugs. It is a combination of medicines used to treat type 2 diabetes mellitus in adults. It helps control blood sugar levels in people with diabetes.
Switglim MV 2/0.3 Tablet ER is a combination of three antidiabetic medicines:
What is Switglim MV 2/0.3 Tablet ER?
Switglim MV 2/0.3 Tablet ER is a combination medication containing Glimepiride, Metformin, and Voglibose. This medication is used to treat type 2 diabetes mellitus (DM). It improves blood glucose levels in adults when taken alongside proper diet and regular exercise. Glimepiride reduces blood sugar by increasing insulin release from the pancreas. Metformin lowers glucose production in the liver and enhances insulin sensitivity. Voglibose inhibits alpha-glucosidase, lowering postprandial glucose levels after meals. This combination is not indicated for Type 1 DM treatment.
What are the possible side effects of Switglim MV 2/0.3 Tablet ER?
Possible side effects of Switglim MV 2/0.3 Tablet ER include hypoglycemia (low blood sugar), nausea, diarrhea, altered taste, flatulence, stomach pain, headache, skin rash, and respiratory tract infection.
Are there any specific conditions in which Switglim MV 2/0.3 Tablet ER should not be taken?
Switglim MV 2/0.3 Tablet ER must not be used by patients with known allergy to any of its components or excipients, and those with severe kidney disease, inflammatory bowel disease (IBD), colonic ulcers, or underlying metabolic acidosis including diabetic ketoacidosis.
Is it safe to take alcohol while I am also taking Switglim MV 2/0.3 Tablet ER?
No, taking alcohol with Switglim MV 2/0.3 Tablet ER is not advised. This combination can lower blood sugar levels (hypoglycemia) and increase the risk of lactic acidosis.
Can the use of Switglim MV 2/0.3 Tablet ER cause hypoglycemia?
Yes, Switglim MV 2/0.3 Tablet ER can cause hypoglycemia (low blood sugar level). Symptoms of hypoglycemia include nausea, headache, irritability, hunger, sweating, dizziness, fast heart rate, and feelings of anxiety or shakiness. It is more likely to occur if you miss meals, drink alcohol, over-exercise, or take other antidiabetic medication simultaneously. Regular monitoring of blood sugar levels is crucial. Keep glucose tablets, honey, or fruit juice readily accessible.
What are the instructions for storage and disposal of Switglim MV 2/0.3 Tablet ER?
Store this medication in its original package or container, tightly closed. Follow instructions provided on the label or packaging. Discard unused medicine; do not give it to pets, children, or other people.
Take this medicine in the dose and duration as advised by your doctor. Swallow it as a whole. Do not chew, crush, or break it. Switglim MV 2/0.3 Tablet ER is to be taken empty stomach.
- Take it with food to lower your chance of having an upset stomach.
- It can cause hypoglycemia (low blood sugar level) when used with other antidiabetic medicines, alcohol, or if you delay or miss a meal. Carry a sugar source with you for immediate relief.
- Your doctor may check your liver function regularly. Inform your doctor if you develop symptoms such as abdominal pain, loss of appetite, or yellowing of the eyes or skin (jaundice).
- No common side effects listed.
Alcohol
It is unsafe to consume alcohol with Switglim MV 2/0.3 Tablet ER.
Breastfeed
Switglim MV 2/0.3 Tablet ER is probably unsafe to use during breastfeeding. Limited human data suggests that the drug may pass into the breastmilk and harm the baby.
Pregnancy
Switglim MV 2/0.3 Tablet ER may be unsafe to use during pregnancy. Although there are limited studies in humans, animal studies have shown harmful effects on the developing baby. Your doctor will weigh the benefits and any potential risks before prescribing it to you. Please consult your doctor.
